Open-label, prospective trial of olanzapine in adolescents with subaverage intelligence and disruptive behavioral disorders

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 45, Issue 8, 2006, Pages 928-935

  Handen, Benjamin L ^a,c   Hardan, Antonio Y ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Adolescents; Atypical antipsychotic agents; Disruptive behavior disorders; Mental retardation; Olanzapine

Indexed keywords

OLANZAPINE; PROLACTIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADOLESCENT; APPETITE DISORDER; ARTICLE; CHECKLIST; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONSTIPATION; DISEASE SEVERITY; DISRUPTIVE BEHAVIOR; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; HOSPITALIZATION; HUMAN; HYPERSALIVATION; LEG EDEMA; LEG PAIN; MALE; MENTAL DEFICIENCY; MOOD DISORDER; NAUSEA; OPEN STUDY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROSPECTIVE STUDY; RASH; RIGIDITY; SEDATION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SUICIDAL IDEATION; SWEATING; TREMOR; WEIGHT GAIN; XEROSTOMIA;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; BENZODIAZEPINES; FEMALE; HUMANS; INTELLIGENCE; MALE; PROSPECTIVE STUDIES;

EID: 33746432079     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.chi.0000223312.48406.6e     Document Type: Article

References (27)

1. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL, Risperidone Disruptive Behavior Study Group (2002), Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 159:1337-1346
2. Aman MG, Singh NN (1994), Aberrant Behavior Checklists-Community. Supplementary Manual. East Aurora, NY: Slosson Educational Publications
3. Aman MG, Singh NN, Stewart AW, Field CJ (1985), The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 89:485-491
4. Beasley CM, Tollefson GD, Tran PV (1997), Safety of olanzapine. J Clin Psychiatry Suppl 10:13-17
5. Bymaster FP (1997), Efficacy of olanzapine. J Clin Psychiatry Suppl 19:7-12
6. Emerson E (2003), Prevalence of psychiatric disorders in children and adolescents with and without intellectual disability. J Intellect Disabil Res 47:1-58
7. Findling RL, Kusumaker V, Daneman D, Moshang T, De Smedt G, Binder C (2003), Prolactin levels during long-term risperidone treatment in children and adolescents. J Clin Psychiatry 64:1362-1369
8. Friedlander R, Lazar S, Klancnik J (2001), Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities. Can J Psychiatry 46:741-745
9. Goyette CH, Conners CK, Ulrich RF (1978), Normative data on revised Conners Parent and Teacher Rating Scales. Abnorm Child Psychol 6:221-236
10. Guy W (1976a), Dosage Record and Treatment Emergent Symptoms Scale, ECDEU Assessment Manual for Psychopharmacology (Revised). DHEW publication (ADM) 76-338. Washington, DC: U.S. Department of Health, Education and Human Welfare, pp 223-244
11. Guy W (1976b), Abnormal involuntary movement scale, In: ECDEU Assessment Manual for Psychopharmacology (Revised). DHEW publication (ADM) 76-338. Washington, DC: U.S. Department of Health, Education and Human Welfare, pp 534-537
12. Handen BL, Janosky J, McAuliffe S, Breaux AM, Feldman H (1994), Prediction of response to methylphenidate among children with ADHD and mental retardation. J Am Acad Child Adolesc Psychiatry 33:1185-1193
13. Handen BL, Feldman H, Lurier M, Husar PJ (1999), Efficacy of methylphenidate among preschoolers with developmental disabilities and ADHD. J Am Acad Child Adolesc Psychiatry 38:805-812
14. Hill BK, Balow EA, Bruininks RH (1985), A national study of prescribed drugs in institutions and community residential facilities for mentally retarded people. Psychopharmacol Bull 21:279-284
15. Janowsky DS, Barnhill LJ, Davis JM (2003), Olanzapine for self-injurious, aggressive, and disruptive behaviors in intellectually disabled adults: a retrospective, open-label, naturalistic trial. J Clin Psychiatry 64:1258-125
16. Madrid AL, State MW, King BH (2000), Pharmacologic management of psychiatric and behavioral symptoms in mental retardation. Child Adolesc Psychiatry Clin N Am 9:225-243
17. Markowitz JS, Brown CS, Joore TR (1999), Atypical antipsychotics. Part I: Pharmacology, pharmacokinetics, and efficacy. Ann Pharmacother 33:73-85
18. Marshburn ED, Aman MG (1992), Factor validity and norms for the Aberrant Behavior Checklist in a community sample of children with mental retardation. J Autism Dev Disord 22:357-373
19. McDonough M, Hillery J, Kennedy N (2000), Olanzapine for chronic, stereotypic self-injurious behaviour: a pilot study in seven adults with intellectual disability. J Intellect Disabil Res 44:677-684
20. Olson DA, Ingram W, Mann JR (2002), Combination of olanzapine and divalproex for agitation in individuals with profound mental retardation. J Clin Psychopharmacol 22:529-530
21. Pearson DA, Aman MG (1994), Ratings of hyperactivity and developmental indices: should clinicians correct for developmental level? J Autism Dev Disord 24:395-411
22. Rating scales and assessment instruments for use in pediatric psychopharmacology research (1985), Psychopharmacol Bull 21:713-1124
23. Rinck C (1998), Epidemiology and psychoactive medication. In: Psychotropic Medications and Developmental Disabilities: The International Consensus Handbook, Reiss T, Aman MG, eds. Columbus: Ohio State University Nisonger Center, pp 31-44
24. Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A, Risperidone Conduct Study Group (2002), Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 41:1026-1036
25. Vieweg W, Sood A, Pandurangi A, Sliverman J (2005), Newer antipsychotic drugs and obesity in children and adolescents. How should we assess drug-associated weight gain? Acta Psychiatr Scand 111:177-184
26. Williams H, Clarke R, Bouras N, Martin J, Holt G (2000), Use of the atypical antipsychotics olanzapine and risperidone in adults with intellectual disability. J Intellect Disabil Res 44:164-169
27. Woods SW (2003), Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 64:663-667